- Report
- November 2022
- 150 Pages
Global
From €4282EUR$4,850USD£3,716GBP
- Report
- July 2024
- 153 Pages
Global
From €3190EUR$3,613USD£2,768GBP
€3753EUR$4,250USD£3,256GBP
- Report
- July 2024
- 91 Pages
Global
From €3500EUR$4,246USD£3,144GBP
- Report
- November 2023
- 87 Pages
Global
From €3500EUR$4,246USD£3,144GBP
- Report
- November 2023
- 125 Pages
Global
From €3500EUR$4,246USD£3,144GBP
- Report
- January 2025
- 132 Pages
Global
From €839EUR$950USD£728GBP
- Report
- January 2025
- 132 Pages
Global
From €839EUR$950USD£728GBP
- Report
- January 2025
- 132 Pages
Global
From €839EUR$950USD£728GBP
- Report
- July 2024
- 132 Pages
Global
From €839EUR$950USD£728GBP
- Report
- November 2021
- 1032 Pages
Global
From €4415EUR$5,000USD£3,831GBP
- Book
- April 2015
- 264 Pages
- Book
- January 2024
- 496 Pages
- Book
- January 2023
- 200 Pages
- Book
- November 2011
Global

A diagnostic biomarker is a biological molecule or gene that is used to identify a particular disease or condition. It is used to diagnose, monitor, and predict the progression of a disease or condition. Diagnostic biomarkers are used to detect the presence of a disease or condition, to determine the severity of the disease or condition, and to monitor the effectiveness of treatments. Diagnostic biomarkers are used in a variety of medical fields, including oncology, neurology, cardiology, and infectious diseases.
Diagnostic biomarkers are typically identified through a variety of methods, including genetic sequencing, proteomics, and metabolomics. These methods allow for the identification of biomarkers that are specific to a particular disease or condition.
The diagnostic biomarker market is a rapidly growing field, with many companies developing and marketing diagnostic biomarkers. Companies in this market include Illumina, Thermo Fisher Scientific, Qiagen, Roche, and Agilent Technologies. Show Less Read more